Hanx Biopharmaceuticals (Wuhan) Co., Ltd.

HK$27.00As of Sun 8 Nov 2026, 12:00 UTC
HKEX:3378Healthcare
Country Hong Kong
PE (Fwd) •••
TSR 10Y CAGR —
Div yield —
ROE —
Biotechnology
Beta (5Y) —
PE TTM —
TSR TTM —
Mkt cap HK$3.678B
ROIC —
SE Grade™
Value
Quality
Moat
Consensus
Reference
$29
8.44%
(22.78%)
Hold 10|10|1|0|10
4Q25
1Q26
2Q26
3Q26
Earnings per share¥
0.32
0.34
0.38
0.42
28.33%
35.95%
35.58%
39.24%
Revenue¥M
245.9
255.3
262.1
261.1
10.92%
11.00%
12.79%
7.94%
Peers (US$469.1M)
Cap (US$)
PE
478.7M
30.07x
475.3M
—
462.3M
43.75x
Capital
TTM
5Y
10Y
Leveragex
1.250
5.052
4.084
EBIT/Intx
5.500
0.190
0.184
Own earn%
42.73
(44.95)
(45.54)
Sh yield%
45.45
26.35
29.84
Owners
Insiders/Inst%
0.23
76.04
Short interest%
1.63
SBC / revenue%
1.86
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
9
Op margin range%
14–19
$1 testx
—
Incr. ROIC%
14